AF
LUCD icon

Allworth Financial’s Lucid Diagnostics LUCD Stock Holding History

Allworth Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360 Buy
313
+242
+341% +$308 ﹤0.01% 4811
2025
Q4 		$78 Sell
71
-126
-64% -$141 ﹤0.01% 4806
2025
Q3 		$199 Buy
197
+87
+79% +$95 ﹤0.01% 4603
2025
Q2 		$127 Hold
110
– – ﹤0.01% 4373
2025
Q1 		$147 Hold
110
– – ﹤0.01% 3915
2024
Q4 		$91 Sell
110
-57
-34% -$50 ﹤0.01% 3848
2024
Q3 		$137 Buy
167
+10
+6% +$8 ﹤0.01% 3641
2024
Q2 		$132 Hold
157
– – ﹤0.01% 3588
2024
Q1 		$128 Buy
+157
New +$204 ﹤0.01% 3495

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Allworth Financial's LUCD Position: Q1 2026 in Review

Allworth Financial increased its Lucid Diagnostics (LUCD) stake by 341% in Q1 2026, buying an estimated $308 and bringing the position to 313 shares worth $360. The position accounts for ﹤0.01% of the portfolio, ranked #4811.

Allworth Financial first reported a position in LUCD in Q1 2024 and has held it in 9 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Allworth Financial held 313 shares of Lucid Diagnostics worth $360 as of Q1 2026.
  • Allworth Financial bought 242 Lucid Diagnostics shares in Q1 2026, an estimated $308.
  • Lucid Diagnostics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4811 holding.
  • Allworth Financial first reported a position in Lucid Diagnostics in Q1 2024 and has held it in 9 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.